Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence

References

• Varga C, Maglio M, Ghobrial IM, et al. Current use of monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 181(4):447–459. 2018.
   PubMed Web of Science ®Google Scholar
• Köhler M, Greil C, Hudecek M, et al. Current developments in immunotherapy in the treatment of multiple myeloma. Cancer. 2018;124(10):2075–2085. .
   PubMed Web of Science ®Google Scholar
• Bonello F, Mina R, Boccadoro M, et al. Therapeutic monoclonal antibodies and antibody products: current practices and development in multiple myeloma. Cancers (Basel). 2019;12(1):19. Basel. .
   Web of Science ®Google Scholar
• Ntanasis-Stathopoulos I, Gavriatopoulou M, Terpos E. Antibody therapies for multiple myeloma. Expert Opin Biol Ther. 2020;20(3):295–303. .
   PubMed Web of Science ®Google Scholar
• Wudhikarn K, Wills B, Lesokhin AM. Monoclonal antibodies in multiple myeloma: current and emerging targets and mechanisms of action. Best Pract Res Clin Haematol. 2020 Mar;331:101143. Epub 2020 Jan11. PMID: 32139009.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Accardi F, Marchica V, et al. Novel targets for the treatment of relapsing multiple myeloma. Expert Rev Hematol. 12(7):481–496. 2019.
   PubMed Web of Science ®Google Scholar
• Iftikhar A, Hassan H, Iftikhar N, et al. Investigational monoclonal antibodies in the treatment of multiple myeloma: a systematic review of agents under clinical development. Antibodies. 2019;8(2):34. Basel.
   Web of Science ®Google Scholar
• Cohen AD. Myeloma: next generation immunotherapy. Hematology Am Soc Hematol Educ Program. 2019;2019(1):266–272.
   PubMedGoogle Scholar
• Musto P. Monoclonal antibodies and multiple myeloma: all in all it’s just another brick in the wall? Oncologist. 2018;23(5):511–515.
   PubMed Web of Science ®Google Scholar
• Bonello F, D’Agostino M, Moscvin, et al. CD38 as an immunotherapeutic target in multiple myeloma. Expert Opin Biol Ther. 2018;18(12):1209–1221. .
   PubMed Web of Science ®Google Scholar
• Frerichs KA, Nagy NA, Lindenbergh PL, et al. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. Expert Rev Clin Immunol. 2018;14(3):197–206.
   PubMed Web of Science ®Google Scholar
• Plesner T, van de Donk N, Richardson PG. Controversy in the use of CD38 antibody for treatment of myeloma: is high CD38 expression good or bad? Cells. 2020 Feb 6;9(2):E378. PMID: 32041300.
   PubMed Web of Science ®Google Scholar
• van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13–29.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma. Cancer. 125(14):2364–2382. 2019.
   PubMed Web of Science ®Google Scholar
• Abdallah N, Kumar SK. Daratumumab in untreated newly diagnosed multiple myeloma. Ther Adv Hematol. 2019;23:2040620719894871(eCollection).
   Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 378(6):518–528. 2018.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132–141.
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 380(22):2104–2115. 2019.
   PubMed Web of Science ®Google Scholar
• Bahlis N, Facon T, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant: updated analysis of maia. Blood. 2019;134(Supplement_1):1875.
   Google Scholar
• Usmani S, Facon T, Kumar S, et al. Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA. J Clin Oncol. 2019;37(15):8038.
   Web of Science ®Google Scholar
• Perrot A, Facon T, Plesner T, et al. Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA). J Clin Oncol. 2019;37(15):8016. .
   Web of Science ®Google Scholar
• Durie BGM, Kumar SK, Usmani SZ, et al. Effectiveness of daratumumab in combination with lenalidomide and dexamethasone (DRd) Vs. common standard-of-care regimens in patients with non-transplant newly diagnosed multiple myeloma (NDMM). Blood. 2019;134(Supplement_1):1830.
   Google Scholar
• Dimopoulos MA, Cavo M, Mateos MV, et al. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT). Leuk Lymphoma. 2020;61(3):714–720. .
   PubMed Web of Science ®Google Scholar
• Stege CAM, Nasserinejad K, Levin MD, et al. Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (idd) in unfit and frail newly diagnosed multiple myeloma (NDMM) patients; first interim safety analysis of the phase II HOVON 143 study. Blood. 2018;132(Supplement 1):596.
   Google Scholar
• Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 394(10192):29–38. 2019.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Moreau P, van der Velden VHJ, et al. Efficacy of daratumumab + bortezomib/thalidomide/dexamethasone (d-vtd) in transplant-eligible newly diagnosed multiple myeloma based on minimal residual disease status: analysis of cassiopeia. HemaSphere. 2019;3:391–392.
   Google Scholar
• Hulin C, Moreau P, Attal M, et al. on behalf of IFM and HOVON; Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study. J Clin Oncol. 2019;37(15):8016. .
   Web of Science ®Google Scholar
• Roussel M, Moreau P, Attal M, et al. Improvement in health-related quality of life for newly diagnosed multiple myeloma transplant-eligible patients treated with daratumumab, bortezomib, thalidomide, and dexamethasone: CASSIOPEIA study. HemaSphere. 2019;3:630.
   Google Scholar
• Moreau P, Zweegman S, Perrot A, et al. Evaluation of the prognostic value of positron emission tomography-computed tomography (PET-CT) at diagnosis and follow-up in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients treated in the phase 3 cassiopeia study: results of the cassiopeia companion study. Blood. 2019;134(Supplement_1):692.
   Google Scholar
• Moreau P, Attal M, Facon T, et al. A matching-adjusted indirect comparison (MAIC) of daratumumab-bortezomib-thalidomide-dexamethasone (D-VTd) versus bortezomib-lenalidomide-dexamethasone (VRd) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) who are transplant eligible. Clin Lymphoma Myeloma Leukemia. 2019;19(10):e199–e200. .
   Web of Science ®Google Scholar
• Sonneveld P, Dejoie T, Zweegman S, et al. A matching-adjusted indirect comparison (MAIC) of bortezomib-thalidomide-dexamethasone (VTd) and daratumumab plus VTd (D-VTd) versus bortezomib-cyclophosphamide- dexamethasone (VCd) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) who are transplant eligible (TE). Clin Lymphoma Myeloma Leukemia. 2019;19(10):e201–e202.
   Web of Science ®Google Scholar
• Voorhees P, Kaufman JL, Laubach J, et al. Daratumumab + lenalidomide, bortezomib & dexamethasone improves depth of response in transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Clin Lymphoma Myeloma Leukemia. 2019;19(10):e353–e354.
   Web of Science ®Google Scholar
• Jabubowiak AJ, Chari A, Lonial S, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): updated results from an open-label, phase 1b study J. Clin Oncol. 2017;35(15):8000. .
   Google Scholar
• Costa LJ, Chhabra S, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based dara-krd consolidation in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2019;134(Supplement_1):860.
   PubMedGoogle Scholar
• Landgren O, Hultcrantz M, Lesokhin AM, et al. Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: a clinical and correlative phase 2 study. Blood. 2019;134(Supplement_1):862. .
   Google Scholar
• Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol. 2019;185(3):492–502. .
   PubMed Web of Science ®Google Scholar
• Rifkin R, Melear JM, Faber E, et al. Daratumumab (DARA) maintenance therapy improves depth of response and results in durable progression-free survival (PFS) following dara plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): update of the lyra study. Blood. 2019;134(Supplement_1):863.
   Google Scholar
• Kapoor P, Gertz MA, Laplant B, et al. Phase 2 trial of daratumumab, ixazomib, lenalidomide and modified dose dexamethasone in patients with newly diagnosed multiple myeloma. Blood. 2019;134(Supplement_1):864. .
   Google Scholar
• Facon T, San-Miguel J, Usmani S, et al. Comparative effectiveness of front-line treatments for patients with newly diagnosed multiple myeloma who are transplant ineligible. HemaSphere. 2019;3:640.
   Google Scholar
• Xu W, Li D, Sun Y, et al. Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis. Eur J Haematol. 2019;103(6):542–551. .
   PubMed Web of Science ®Google Scholar
• Sekine L, Ziegelmann PK, Manica D, et al. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials. Crit Rev Oncol Hematol. 2019;143:102–116.
   PubMed Web of Science ®Google Scholar
• Thein KZ, Htut TW, Win MA, et al. Efficacy of upfront daratumumab combination regimen in patients with newly diagnosed multiple myeloma. Blood. 2019;134(Supplement_1):3158. .
   Google Scholar
• Htut TW, Win MA, Swarup S, et al. Tolerability in patients with multiple myeloma treated with daratumumab: a systematic review and meta-analysis of phase III randomized controlled trials. Blood. 2019;134(Supplement_1):1873. .
   PubMedGoogle Scholar
• Al Hadidi S, Kamble R, Miller-Chism CN, et al. Safety analysis of five randomized controlled studies of daratumumab in patients with multiple myeloma. Blood. 2019;134(Supplement_1):3175. .
   Google Scholar
• Ramasamy K, Dhanasiri S, Thom H, et al. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. Leuk Lymphoma. 2020;61(3):668–679. .
   PubMed Web of Science ®Google Scholar
• Blommestein HM, van Beurden-tan CHY, Franken MG, et al. Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. Haematologica. 2019;104(5):1026–1035. .
   PubMed Web of Science ®Google Scholar
• Gil-Sierra MD, Gimeno-Ballester V, Fenix-Caballero S, et al. Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients. Eur J Haematol. 2020 Mar 7. DOI:10.1111/ejh.13407.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Broijl A, Gay T, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). J Clin Oncol. 2019;37(15):8055. .
   Web of Science ®Google Scholar
• Shah ND, Lutska Y, Pei H, et al. Daratumumab (DARA) plus lenalidomide versus lenalidomide alone as maintenance treatment in patients with newly diagnosed multiple myeloma (NDMM) after frontline autologous stem cell transplant (ASCT): use of minimal residual disease (MRD) as a novel primary endpoint in the phase 3 auriga study. Blood. 2019;134(Supplement_1):1829.
   Google Scholar
• Zweegman S, Usmani SZ, Chastain K, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS). J Clin Oncol. 2019;37(15):8056. .
   Web of Science ®Google Scholar
• Ye JC, Boonstra PS, Boyer DF, et al. A phase 2 study with minimal residual disease (MRD) driven adaptive strategy in treatment for newly diagnosed multiple myeloma with upfront daratumumab-based therapy. Blood. 2019;134(Supplement_1):3191. .
   Google Scholar
• Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019;134(8):668–677.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Nahi H, Legiec W, et al. Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM). COLUMBA J Clin Oncol. 2019;37(15_suppl):8005.
   Web of Science ®Google Scholar
• Chari A, San-Miguel J, McCarthy H, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy: pleiades study update. Blood. 2019;134(Supplement_1):3152. .
   Google Scholar
• Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-cd38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176–3187. .
   PubMed Web of Science ®Google Scholar
• Weisel K, Asemissen AM, Schieferdecker A, et al. Isatuximab, carfilzomib, lenalidomide and dexamethasone (I-KRd) in front-line treatment of high-risk multiple myeloma: results of the safety run-in cohort in the phase II, multicenter GMMG-CONCEPT trial. Clin Lymphoma Myeloma Leukemia. 2019;19(10):e17. .
   Web of Science ®Google Scholar
• Asemissen AM, Autenrieth S, Bieber K, et al. Prospective monitoring of immune signatures in newly diagnosed high risk multiple myeloma patients under treatment with Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd): first results of the GMMG-CONCEPT trial. Clin Lymphoma Myeloma Leukemia. 2019;19(10):e141–e142. .
   Web of Science ®Google Scholar
• Ocio EM, Rodriguez Otero P, Bringhen S, et al. Preliminary results from a phase i study of isatuximab (ISA) in Combination with bortezomib, lenalidomide, dexamethasone (VRd), and in patients with newly diagnosed multiple myeloma (NDMM) non-eligible for transplant. Blood. 2018 1;32(Supplement_1):595.
   Google Scholar
• Trudel S, Moreau P, Touzeau C. Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective. Onco Targets Ther. 2019;12:5813–5822. .
   PubMed Web of Science ®Google Scholar
• Salwender H, Bertsch U, Weisel K, et al. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer. 2019;19(1):504. .
   PubMed Web of Science ®Google Scholar
• Gadi N, Schmidt L, Ahn J, et al. Elotuzumab as post-autologous stem cell transplant consolidation in patients with high-risk myeloma. Blood. 2019;134(Supplement_1):3141. .
   Google Scholar
• Berdeja JG, Gregory TK, Kambhampati S, et al. A phase 2 study to assess the feasibility and tolerance of the combination of elotuzumab, LENALIDOMIDE, AND DEXAMETHASONe (ERd) in the induction, consolidation, and maintenance treatment of transplant-eligible patients newly DIAGNOSED WITH MULTIPLE MYELOMa (MM). Blood. 2019;134(Supplement_1):603.
   Google Scholar
• Schmidt EV. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. Semin Immunopathol. 2018;41(1):21–30.
   PubMed Web of Science ®Google Scholar
• Oliva S, Troia R, D’Agostino M, et al. Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. Front Immunol. 2018;9:2749.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Bal S, Badros AZ. Lessons learned from checkpoint blockade targeting PD-1 in MULTIPLE MYELOMA. Cancer Immunol Res. 2019;7(8):1224–1229.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Schjesvold F, Oriol A, et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol. 6(9):e448–e458. 2019.
   PubMed Web of Science ®Google Scholar
• D’Souza A, Hari P, Pasquini M, et al. A phase 2 study of pembrolizumab during lymphodepletion after autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2019;25(8):1492–1497. .
   PubMed Web of Science ®Google Scholar
• Bansal M, Siegel DS, Ahn J, et al. Two year update of phase II trial of pembrolizumab, lenalidomide and dexamethasone as post -autologous stem cell transplant consolidation in patients with high-risk multiple myeloma. Blood. 2019;134(Supplement_1):1911. .
   Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study. J Clin Oncol. 2016;34(23):2698–2704. .
   PubMed Web of Science ®Google Scholar
• Skarbnik AP, Donato ML, Korngold R, et al. Safety and efficacy data for combined checkpoint inhibition with ipilimumab (Ipi) and nivolumab (Nivo) as consolidation following autologous stem cell transplantation (ASCT) for high-risk hematological malignancies - CPIT-001 trial. Blood. 2018;132(Supplement_1):256. .
   Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. .
   PubMed Web of Science ®Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–2590. .
   PubMed Web of Science ®Google Scholar
• Ahn IE, Mailankody S, Korde N, et al. Dilemmas in treating smoldering multiple myeloma. J Clin Oncol. 2015 Jan 1;33(1):115–123. . Epub 2014 Nov 24. PMID:25422486.
   PubMed Web of Science ®Google Scholar
• Cocito F, Mangiacavalli S, Ferretti VV, et al. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice. Leuk Lymphoma. 2019;60(12):2968–2974. .
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 17(8):1127–1136. 2016.
   PubMed Web of Science ®Google Scholar
• Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020 Apr 10;38(11):1126–1137.
   Google Scholar
• Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015 Sep;1(6):746–754. PMID: 26181891.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Gonzalez-Velez M. Treatment of smoldering multiple myeloma: expectant observation should still be the standard. Am Soc Clin Oncol Educ Book. 2020 Mar;40(40):1–7. . PMID: 32207672.
   PubMedGoogle Scholar
• Joseph NS, Dhodapkar MV, Lonial S. the role of early intervention in high-risk smoldering myeloma. Am Soc Clin Oncol Educ Book. 2020 Mar;40(40):1–9. . PMID: 32182141.
   PubMedGoogle Scholar
• Biran N, Vesole DH, Donato ML. Treatment of smoldering myeloma: problems with study design as well as biological and clinical implications. J Clin Oncol. 2020. Mar 11 JCO1902972. DOI:10.1200/JCO.19.02972. [ Epub ahead of print] PMID: 32160077; JCO.19.02972.
   PubMed Web of Science ®Google Scholar
• Landgren O, Chari A, Cohen YC, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open label, multicenter phase 2 study (CENTAURUS). Leukemia. 2020. PMID 32024950 [Online ahead of print]. DOI:10.1038/s41375-020-0718-z.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Voorhees PM, Goldschmidt H, et al. Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA. J Clin Oncol. 2018;36(15_suppl):8062. .
   Web of Science ®Google Scholar
• Nadeem O, Redd R, Stampleman LV, et al. a phase ii study of daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma: first report of efficacy and safety. Blood. 2019;134(Supplement_1):1898. .
   Google Scholar
• Manasanch EE, Jagannath S, Lee HC, et al. A multicenter phase ii single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM). Blood. 2019;134(Supplement_1):3116. .
   Google Scholar
• Jagannath S, Laubach J, Wong E, et al. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol. 2018;182(4):495–503. .
   PubMed Web of Science ®Google Scholar
• Liu C, Ghobrial I, Bustoros M, et al. Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood. 2018;132(Supplement_1):154. .
   Google Scholar
• Manasanch EE, Han G, Mathur R, et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019;3(18):2712. .
   PubMed Web of Science ®Google Scholar
• Brighton TA, Khot A, Harrison SJ, et al. Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma. Clin Cancer Res. 2019;25(13):3772–3775. .
   PubMed Web of Science ®Google Scholar
• Zamagni E, Tacchetti P, Pantani L, et al. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy. Expert Rev Hematol. 2018;11(5):423–435.
   PubMed Web of Science ®Google Scholar
• Musto P, La Rocca F. Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real life studies and meta-analyses. Expert Rev Hematol. 2020 Mar 10;13(4):331–349. PMID: 32153224 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Killock D. New daratumumab quadruplets and triplets for newly diagnosed MM. Nat Rev Clin Oncol. 2019 Sep;16(9):526–527. .
   PubMed Web of Science ®Google Scholar
• Takamatsu H, Iida S, Shibayama H, et al. Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study. Int J Hematol. 2020 Jan 30 Epub ahead of print. DOI:10.1007/s12185-020-02825-w.
   Web of Science ®Google Scholar
• Kubo K, Hori M, Ohta K, et al. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. Int J Hematol. 2020 Jan;111(1):65–74. Epub 2019 Nov 7.
   PubMed Web of Science ®Google Scholar
• Oriol A. A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma. Expert Rev Hematol. 2020 Mar 21:1–11 Epub ahead of print. DOI:10.1080/17474086.2020.1744432.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Jakubowiak AJ, McCarthy PL, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020 Feb 13;10(2):17. .
   PubMed Web of Science ®Google Scholar
• Lu SX. Modern treatments and future directions for newly diagnosed multiple myeloma patients. Best Pract Res Clin Haematol. 2020 Mar;33(1):101151. .
   PubMed Web of Science ®Google Scholar
• Jelinek T. Venetoclax: the first anti-myeloma agent with a reliable biomarker. Br J Haematol. 2020 Feb 3. DOI:10.1111/bjh.16493.
   Web of Science ®Google Scholar
• Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019 Aug 22;381(8):727–738.
   PubMed Web of Science ®Google Scholar
• Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020 Feb 13;34(4):985–1005.
   Web of Science ®Google Scholar